6.50
price up icon6.38%   0.39
after-market After Hours: 6.72 0.22 +3.38%
loading
Immuneering Corp stock is traded at $6.50, with a volume of 2.28M. It is up +6.38% in the last 24 hours and up +9.24% over the past month. Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
See More
Previous Close:
$6.11
Open:
$6.24
24h Volume:
2.28M
Relative Volume:
1.52
Market Cap:
$270.21M
Revenue:
$317.00K
Net Income/Loss:
$-53.47M
P/E Ratio:
-3.4392
EPS:
-1.89
Net Cash Flow:
$-49.31M
1W Performance:
+2.20%
1M Performance:
+9.24%
6M Performance:
+420.00%
1Y Performance:
+171.97%
1-Day Range:
Value
$6.1259
$6.54
1-Week Range:
Value
$6.02
$6.99
52-Week Range:
Value
$1.10
$10.08

Immuneering Corp Stock (IMRX) Company Profile

Name
Name
Immuneering Corp
Name
Phone
617-500-8080
Name
Address
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Name
Employee
54
Name
Twitter
Name
Next Earnings Date
2025-08-08
Name
Latest SEC Filings
Name
IMRX's Discussions on Twitter

Compare IMRX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
IMRX
Immuneering Corp
6.50 386.39M 317.00K -53.47M -49.31M -1.89
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
421.15 105.19B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
450.68 60.24B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.86 61.82B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
798.94 49.09B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
351.09 37.52B 4.56B -176.77M 225.30M -1.7177

Immuneering Corp Stock (IMRX) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-13-24 Downgrade Morgan Stanley Equal-Weight → Underweight
Mar-15-24 Downgrade Jefferies Buy → Hold
Mar-15-24 Reiterated Needham Buy
Mar-15-24 Downgrade TD Cowen Outperform → Market Perform
Dec-01-23 Initiated Needham Buy
Jun-26-23 Resumed Oppenheimer Outperform
Apr-19-23 Upgrade Mizuho Neutral → Buy
Apr-19-23 Upgrade Morgan Stanley Underweight → Equal-Weight
Mar-30-23 Initiated Mizuho Neutral
Feb-03-23 Downgrade Morgan Stanley Equal-Weight → Underweight
Jul-08-22 Initiated Chardan Capital Markets Buy
Apr-01-22 Initiated Oppenheimer Outperform
Jan-07-22 Initiated Piper Sandler Overweight
View All

Immuneering Corp Stock (IMRX) Latest News

pulisher
Oct 07, 2025

Insider Stock Purchases: October 07, 2025 - Quiver Quantitative

Oct 07, 2025
pulisher
Oct 07, 2025

Insider Buying: Immuneering (NASDAQ:IMRX) Director Purchases 7,500 Shares of Stock - MarketBeat

Oct 07, 2025
pulisher
Oct 05, 2025

Why Immuneering Corporation stock is in analyst buy zoneEarnings Risk Summary & Growth Focused Stock Reports - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Will Immuneering Corporation stock outperform Nasdaq indexJuly 2025 Setups & Verified Momentum Stock Watchlist - newser.com

Oct 05, 2025
pulisher
Oct 03, 2025

Analyzing recovery setups for Immuneering Corporation investorsMarket Activity Summary & Consistent Profit Focused Trading Strategies - newser.com

Oct 03, 2025
pulisher
Oct 03, 2025

What to expect from Immuneering Corporation in the next 30 daysEarnings Performance Report & Free Community Supported Trade Ideas - newser.com

Oct 03, 2025
pulisher
Oct 02, 2025

Will Immuneering Corporation stock benefit from commodity prices2025 Retail Activity & Weekly High Return Stock Opportunities - newser.com

Oct 02, 2025
pulisher
Oct 02, 2025

Two new option listings and three option delistings on October 2nd - TipRanks

Oct 02, 2025
pulisher
Oct 02, 2025

Immuneering Corporation (NASDAQ:IMRX) Receives $17.75 Consensus PT from Analysts - Defense World

Oct 02, 2025
pulisher
Oct 01, 2025

Insider Stock Purchases: October 01, 2025 - Quiver Quantitative

Oct 01, 2025
pulisher
Oct 01, 2025

Feinberg Peter buys Immuneering Corp (IMRX) shares for $52,730 - Investing.com India

Oct 01, 2025
pulisher
Sep 30, 2025

Positive Trial Data Supports 43% Upside for Immuneering Corporation (IMRX) - Insider Monkey

Sep 30, 2025
pulisher
Sep 30, 2025

Peter Feinberg Acquires 5,000 Shares of Immuneering (NASDAQ:IMRX) Stock - MarketBeat

Sep 30, 2025
pulisher
Sep 30, 2025

Can Immuneering Corporation stock sustain market leadershipEarnings Performance Report & Reliable Breakout Forecasts - newser.com

Sep 30, 2025
pulisher
Sep 30, 2025

Will Product Innovation Drive Rajasthan Gases Limited Stock in YEARInstitutional Buying Trends & Create Your Free Watchlist Instantly - earlytimes.in

Sep 30, 2025
pulisher
Sep 29, 2025

11 Best Fast Money Stocks to Buy Now - Insider Monkey

Sep 29, 2025
pulisher
Sep 29, 2025

Identifying reversal signals in Immuneering Corporation2025 Analyst Calls & Risk Managed Investment Signals - newser.com

Sep 29, 2025
pulisher
Sep 29, 2025

Immuneering Corporation (NASDAQ:IMRX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Sep 29, 2025
pulisher
Sep 27, 2025

Immuneering (NASDAQ:IMRX) Price Target Raised to $20.00 at Chardan Capital - Defense World

Sep 27, 2025
pulisher
Sep 26, 2025

Immuneering to host call on pancreatic cancer treatment data By Investing.com - Investing.com Nigeria

Sep 26, 2025
pulisher
Sep 26, 2025

Immuneering To Discuss Recently Announced Overall Survival Data From Phase 2A Clinical Trial Of Atebimetinib + Mgnp In First-Line Pancreatic Cancer Patients On September 29 - TradingView

Sep 26, 2025
pulisher
Sep 26, 2025

MBX, uniQure among biotechs raising nine-figure sums: Public Equity Report - biocentury.com

Sep 26, 2025
pulisher
Sep 26, 2025

Immuneering to host call on pancreatic cancer treatment data - Investing.com

Sep 26, 2025
pulisher
Sep 26, 2025

Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025 - The Manila Times

Sep 26, 2025
pulisher
Sep 26, 2025

First-Line Pancreatic Cancer Trial Update: Immuneering to Present Survival Data for Atebimetinib + mGnP - Stock Titan

Sep 26, 2025
pulisher
Sep 26, 2025

Immuneering (NASDAQ:IMRX) Price Target Raised to $30.00 at Oppenheimer - Defense World

Sep 26, 2025
pulisher
Sep 25, 2025

To vanquish pancreatic at last? Immuneering scores in phase II - BioWorld MedTech

Sep 25, 2025
pulisher
Sep 25, 2025

Immuneering Stock Rises 21.7% on Supply Agreement With LLY - MSN

Sep 25, 2025
pulisher
Sep 25, 2025

Immuneering: Positive Pancreatic Cancer Data Atebimetinib Leads To Q4 2025 Catalyst (IMRX) - Seeking Alpha

Sep 25, 2025
pulisher
Sep 25, 2025

Mizuho reiterates Outperform rating on Immuneering stock after positive data - Investing.com India

Sep 25, 2025
pulisher
Sep 25, 2025

Immuneering Asset Nearly Doubles Overall Survival in Pancreatic Cancer After 9 Months - NewsBreak: Local News & Alerts

Sep 25, 2025
pulisher
Sep 25, 2025

IMRX: Oppenheimer Raises Target Price Amidst Outperform Rating | - GuruFocus

Sep 25, 2025
pulisher
Sep 25, 2025

Oppenheimer Forecasts Strong Price Appreciation for Immuneering (NASDAQ:IMRX) Stock - MarketBeat

Sep 25, 2025
pulisher
Sep 25, 2025

Immuneering Corporation’s Stock Rollercoaster: What’s Next? - StocksToTrade

Sep 25, 2025
pulisher
Sep 25, 2025

Immuneering price target raised to $30 from $21 at Oppenheimer - TipRanks

Sep 25, 2025
pulisher
Sep 25, 2025

Oppenheimer Maintains Immuneering(IMRX.US) With Buy Rating, Raises Target Price to $30 - 富途牛牛

Sep 25, 2025
pulisher
Sep 25, 2025

Immuneering Corporation (IMRX) PT Raised to $30 at Oppenheimer - StreetInsider

Sep 25, 2025
pulisher
Sep 25, 2025

Mizuho Reiterates Outperform Rating on Immuneering Corporation (IMRX) - StreetInsider

Sep 25, 2025
pulisher
Sep 25, 2025

Why PepGen Shares Are Trading Higher By 112%; Here Are 20 Stocks Moving Premarket - Benzinga

Sep 25, 2025
pulisher
Sep 25, 2025

Needham Maintains Immuneering(IMRX.US) With Buy Rating, Maintains Target Price $11 - 富途牛牛

Sep 25, 2025
pulisher
Sep 25, 2025

Immuneering Announces $25M Securities Purchase Agreement - TipRanks

Sep 25, 2025
pulisher
Sep 25, 2025

Promising Clinical Trial Results and Favorable Safety Profile Support Buy Rating for Immuneering - TipRanks

Sep 25, 2025
pulisher
Sep 25, 2025

IMRX Soars On Pancreatic Cancer Data, PEPG Sets DM1 Splicing Correction Record, CLPT On Watch - RTTNews

Sep 25, 2025
pulisher
Sep 25, 2025

Immuneering Reveals Pricing Of 18.96 Mln Shares Public Offering At $9.23/Shr - Nasdaq

Sep 25, 2025

Immuneering Corp Stock (IMRX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Immuneering Corp Stock (IMRX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Morales Mallory
Chief Accounting Officer
Oct 01 '25
Buy
6.39
300
1,917
27,533
Neufeld Leah R
CHIEF PEOPLE OFFICER
Oct 01 '25
Buy
6.38
800
5,103
23,344
Bookman Michael
CHIEF LEGAL OFFICER, SECRETARY
Oct 01 '25
Buy
6.83
1,020
6,966
4,870
Feinberg Peter
Director
Sep 30 '25
Buy
7.03
7,500
52,730
149,266
Feinberg Peter
Director
Sep 29 '25
Buy
7.18
5,000
35,900
141,766
$85.38
price down icon 2.05%
$23.34
price up icon 4.71%
$32.74
price up icon 0.31%
$106.28
price up icon 0.21%
$161.81
price down icon 0.31%
biotechnology ONC
$351.09
price up icon 2.77%
Cap:     |  Volume (24h):